Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Cytochrome P450 Binding and Bioactivation of Tumor-Targeted Duocarmycin Agents

Aaron G. Bart, Goreti Morais, Venu R. Vangala, Paul M. Loadman, Klaus Pors and Emily E. Scott
Drug Metabolism and Disposition January 2022, 50 (1) 49-57; DOI: https://doi.org/10.1124/dmd.121.000642
Aaron G. Bart
Program in Biophysics (A.G.B., E.E.S.) and Departments of Medicinal Chemistry and Pharmacology and Biological Chemistry (E.E.S.), University of Michigan, Ann Arbor, Michigan; Institute of Cancer Therapeutics (G.M., P.M.L., K.P.), Centre for Pharmaceutical Engineering Science (V.R.V.), Faculty of Life Sciences, University of Bradford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Goreti Morais
Program in Biophysics (A.G.B., E.E.S.) and Departments of Medicinal Chemistry and Pharmacology and Biological Chemistry (E.E.S.), University of Michigan, Ann Arbor, Michigan; Institute of Cancer Therapeutics (G.M., P.M.L., K.P.), Centre for Pharmaceutical Engineering Science (V.R.V.), Faculty of Life Sciences, University of Bradford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venu R. Vangala
Program in Biophysics (A.G.B., E.E.S.) and Departments of Medicinal Chemistry and Pharmacology and Biological Chemistry (E.E.S.), University of Michigan, Ann Arbor, Michigan; Institute of Cancer Therapeutics (G.M., P.M.L., K.P.), Centre for Pharmaceutical Engineering Science (V.R.V.), Faculty of Life Sciences, University of Bradford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul M. Loadman
Program in Biophysics (A.G.B., E.E.S.) and Departments of Medicinal Chemistry and Pharmacology and Biological Chemistry (E.E.S.), University of Michigan, Ann Arbor, Michigan; Institute of Cancer Therapeutics (G.M., P.M.L., K.P.), Centre for Pharmaceutical Engineering Science (V.R.V.), Faculty of Life Sciences, University of Bradford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Pors
Program in Biophysics (A.G.B., E.E.S.) and Departments of Medicinal Chemistry and Pharmacology and Biological Chemistry (E.E.S.), University of Michigan, Ann Arbor, Michigan; Institute of Cancer Therapeutics (G.M., P.M.L., K.P.), Centre for Pharmaceutical Engineering Science (V.R.V.), Faculty of Life Sciences, University of Bradford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily E. Scott
Program in Biophysics (A.G.B., E.E.S.) and Departments of Medicinal Chemistry and Pharmacology and Biological Chemistry (E.E.S.), University of Michigan, Ann Arbor, Michigan; Institute of Cancer Therapeutics (G.M., P.M.L., K.P.), Centre for Pharmaceutical Engineering Science (V.R.V.), Faculty of Life Sciences, University of Bradford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Duocarmycin analogs ICT2700 and ICT2726 (shown in boxes, differences colored in red). The ICT2700 analog has been reported to undergo bioactivation by CYP1A1 and CYP2W1 via a specific hydroxylation (red dotted oval) on the chloromethyl indoline substructure (Travica et al., 2013). Spontaneous spirocyclization occurs producing a reactive cyclopropane moiety. DNA adenine bases can be alkylated with this reactive group leading to cytotoxic DNA adducts. The ICT2726 analog does not undergo bioactivation. Instead, this analog can potentially serve as a biomarker for CYP2W1 activity due to the generation of a unique nontoxic metabolite specific to CYP2W1 (Sheldrake et al., 2013).

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Spectral binding experiments of CYP1A1 and CYP2W1 with the seco-duocarmycin enantiomers of ICT2726. Representative difference binding spectra are shown of CYP1A1 (1A1) [(A) and (B)] and CYP2W1 (2W1) [(C) and (D)], with the respective ICT2726 enantiomer. Insets display the difference in peak-trough absorbance (average of two technical duplicates) versus compound concentration and are fit by nonlinear regression to a tight-binding equation. The fitted compound affinities (Kd values) are reported with ± S.E. (error bars).

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Spectral binding experiments of CYP1A1 and CYP2W1 with the seco-duocarmycin enantiomers of ICT2700. Difference binding spectra are shown of CYP1A1 (1A1) [(A) and (B)] and CYP2W1 (2W1) [(C) and (D)] binding the ICT2700 enantiomers. Insets display the difference in peak-trough absorbance (average of two technical duplicates) versus compound concentration and are fit by nonlinear regression to a tight-binding equation. The fitted compound affinities (Kd values) are reported with ± S.E. (error bars).

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    LC-MS chromatograms of ICT compounds incubated with CYP1A1 (1A1) or CYP2W1 (2W1) for 30 minutes; M6 = spirocyclized product. (A) ICT2700 R/S CYP1A1 metabolism. (B) ICT2700 R/S CYP2W1 metabolism. (C) ICT2726 R/S CYP1A1 metabolism (D) ICT2726 R/S CYP2W1 metabolism. AU, absorbance units; ESI+, electrospray ionization in positive mode; MS, mass; M+H, singly protonated mass; RT, retention time.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Co-crystallization structures of CYP1A1 (ribbons) bound to (S)-ICT2726 (A) and (S)-ICT2700 (B) (gray sticks). Electron density is shown as 2Fo – Fc composite omit map contoured at 1.0 σ (blue mesh) around the ligand and heme (black sticks with orange Fe sphere). Potential hydrogen bonds (black dashes), halogen bonds (yellow dashes), and ligand atoms in closest proximity to the heme iron (red dashes) are shown with their corresponding distances.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    X-ray data collection and refinement statistics for P450/ligand structures.

    CYP1A1/(S)-ICT2700 (6UDL)CYP1A1/(S)-ICT2726 (6UDM)
    Data collection
     Space groupP212121P3121
     Cell dimensions (Å)65.37, 196.15, 237.22241.28, 241.28, 125.30
     Molecules/asymmetric unit44
     Resolution (Å)a50.00–2.85 (2.90–2.85)39.64–3.07 (3.14–3.07)
     Total reflectionsa510,182 (17,794)783,762 (35,174)
     Unique reflectionsa72,081 (3,422)77,258 (3,944)
     Redundancya7.1 (5.2)10.1 (8.9)
     Rpima0.080 (0.942)0.054 (0.631)
     <I/σ(I)> a28.0 (2.1)9.7 (1.6)
     CC1/2a0.990 (0.322)0.997 (0.518)
     Completeness (%)a99.8 (97.3)99.0 (85.6)
    Refinement
     Resolution (Å)48.799–2.85039.64–3.10
     No. reflections71,70976,831
     R/Rfree (%)23.8 / 28.720.1 / 22.1
     Ramachandran (%) favored/allowed/outliers96.19 / 3.81/ 0.0097.15 / 2.85 / 0.00
     No. non-H atoms/B factors (Å2)
      Protein15,015 / 68.6015,026 / 80.62
      Ligand54 / 57.62104 / 80.66
      Heme172 / 57.09172 / 68.49
      CHAPS—/—42 / 100.77
      Water1 / 49.31—/—
     RMSD bond (Å)0.0080.007
     RMSD angle (°)0.7650.636
     Coordinate error (Å)0.370.37
    • CC1/2, Pearson correlation coefficient; <I/σ(I)>, average intensity over variation in intensity; R, measure of error between the observed intensities from the diffraction pattern and the predicted intensities calculated from the model; Rfree, measure of error between the observed diffraction pattern intensities from the diffraction pattern and the predicted intensities for a subset of data not used in model refinement; RMSD, root mean square deviation; Rpim, precision-indicating merging R factor

    • a Statistics for highest resolution shell shown in parentheses.

Additional Files

  • Figures
  • Tables
  • Data Supplement

    • Supplemental Data -


      Table S1. Crystallographic data for ICT2700 and ICT2726 small molecule structures.
      Table S2. LC-MS gradient method.
      Figure S1. Structures of ICT2700 and ICT2726 as determined by single molecule X-ray crystallography.


PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 50 (1)
Drug Metabolism and Disposition
Vol. 50, Issue 1
1 Jan 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cytochrome P450 Binding and Bioactivation of Tumor-Targeted Duocarmycin Agents
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

P450 Activation of Duocarmycin Prodrugs

Aaron G. Bart, Goreti Morais, Venu R. Vangala, Paul M. Loadman, Klaus Pors and Emily E. Scott
Drug Metabolism and Disposition January 1, 2022, 50 (1) 49-57; DOI: https://doi.org/10.1124/dmd.121.000642

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

P450 Activation of Duocarmycin Prodrugs

Aaron G. Bart, Goreti Morais, Venu R. Vangala, Paul M. Loadman, Klaus Pors and Emily E. Scott
Drug Metabolism and Disposition January 1, 2022, 50 (1) 49-57; DOI: https://doi.org/10.1124/dmd.121.000642
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolic enzymes in nintedanib metabolism
  • Mechanism of AO Inactivation by Hydralazine
  • Warfarin PBPK modeling with target binding
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics